Racial differences in patterns of treatment among men diagnosed with de novo advanced prostate cancer: A SEER‐Medicare investigation

Cancer statistics, 2018

(2018) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics

(2018) Kathleen A. Cronin et al.   CANCER

Local treatment for metastatic prostate cancer: A systematic review

(2018) Derya Tilki et al.   INTERNATIONAL JOURNAL OF UROLOGY

Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial

(2018) Kim N Chi et al.   LANCET ONCOLOGY

Emerging Therapies in Metastatic Prostate Cancer

(2018) Daniel W. Sonnenburg et al.   Current Oncology Reports

Androgen deprivation therapy for prostate cancer and dementia risk: a systematic review and meta-analysis

(2017) K T Nead et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Newly Diagnosed Metastatic Prostate Cancer: Has the Paradigm Changed?

(2017) Shivashankar Damodaran et al.   UROLOGIC CLINICS OF NORTH AMERICA

Impact of local treatment on overall survival of patients with metastatic prostate cancer: systematic review and meta-analysis

(2017) Arie Carneiro et al.   International Braz J Urol

Prostate Cancer, Version 1.2014

(2017) James L. Mohler et al.   Journal of the National Comprehensive Cancer Network

Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities

(2016) Carol E. DeSantis et al.   CA-A CANCER JOURNAL FOR CLINICIANS

National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers?

(2016) Brandon A. Mahal et al.   CANCER

Disparities in Treatment of Patients With High-risk Prostate Cancer: Results From a Population-based Cohort

(2016) Elyn H. Wang et al.   UROLOGY

Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy

(2016) Maxine Sun et al.   JAMA Oncology

Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer

(2016) Marianne Schmid et al.   JAMA Oncology

Trends in United States Prostate Cancer Incidence Rates by Age and Stage, 1995-2012

(2015) R. M. Hoffman et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Quantifying Observational Evidence for Risk of Fatal and Nonfatal Cardiovascular Disease Following Androgen Deprivation Therapy for Prostate Cancer: A Meta-analysis

(2015) Cecilia Bosco et al.   EUROPEAN UROLOGY

Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations

(2015) Ahmedin Jemal et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Nadir Testosterone Within First Year of Androgen-Deprivation Therapy (ADT) Predicts for Time to Castration-Resistant Progression: A Secondary Analysis of the PR-7 Trial of Intermittent Versus Continuous ADT

(2015) Laurence Klotz et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

(2015) Christopher J. Sweeney et al.   NEW ENGLAND JOURNAL OF MEDICINE

Income inequality and treatment of African American men with high-risk prostate cancer

(2015) David R. Ziehr et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Low rates of adjuvant radiation in patients with nonmetastatic prostate cancer with high-risk pathologic features

(2014) Anusha Kalbasi et al.   CANCER

Racial Disparities in Prostate Cancer–Specific Mortality in Men With Low-Risk Prostate Cancer

(2014) Brandon A. Mahal et al.   Clinical Genitourinary Cancer

Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial

(2014) Oliver Sartor et al.   LANCET ONCOLOGY

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

(2014) Tomasz M. Beer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trends in Disparate Treatment of African American Men With Localized Prostate Cancer Across National Comprehensive Cancer Network Risk Groups

(2014) Brandon A. Mahal et al.   UROLOGY

Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement

(2013) Virginia A. Moyer   ANNALS OF INTERNAL MEDICINE

Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study

(2013) Stephen H. Culp et al.   EUROPEAN UROLOGY

Safety of Megestrol Acetate in Palliating Anorexia-Cachexia Syndrome in Patients with Castration-Resistant Prostate Cancer

(2013) Sungwoo Hong et al.   JOURNAL OF KOREAN MEDICAL SCIENCE

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

(2011) Karim Fizazi et al.   LANCET

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

(2011) Matthew R Smith et al.   LANCET

Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial

(2011) James W Denham et al.   LANCET ONCOLOGY

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

(2009) Celestia S. Higano et al.   CANCER

Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates

(2009) Karim Fizazi et al.   JOURNAL OF CLINICAL ONCOLOGY

Metabolic Complications of Androgen Deprivation Therapy for Prostate Cancer

(2009) Philip J. Saylor et al.   JOURNAL OF UROLOGY

Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials

(2009) David P Dearnaley et al.   LANCET ONCOLOGY